Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

 Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Shots:

  • BlueRock to get $240M in cash as upfront and $360M as development milestones. In 2016, Bayer and Versant Ventures formed a joint venture establishing BlueRock Therapeutics, Bayer currently holds the 40.8% stock in BlueRock and will acquire the remaining stocks with its anticipated closure of transaction in Q3’19
  • The focus of the acquisition is to strengthen Bayer’s cell therapy portfolio with the addition of BlueRock’s CELL+GENE platform and cell therapies pipeline currently focusing on neurology, cardiology & immunology with the expected initiation of the clinical program in Parkinson’s disease in H2’19 and will operate as an independent company
  • BlueRock Therapeutics’ CELL+GENE platform includes a broad intellectual property portfolio and technology platforms including iPSC technology, gene engineering and cell differentiation capabilities and harvests primary cells to develop therapies

Click here to­ read full press release/ article | Ref: Bayer | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post